KPIs & Operating Metrics(New)
Additions To Property And EquipmentAdjusted Income Before TaxAdjusted Income Before Tax By SegmentAssets By SegmentBreakdown Of AssetsCardiovascular/Metabolism/Other RevenueCardiovascular/Metabolism/Other Revenue AnnualConsumer RevenueContractual BoligationsCost Of Products SoldDisaggregated Revenue Mix %Disaggregated RevenuesEarnings Before Taxes On IncomeEbt By SegmentEbt By Segment AnnualEbt Margin By Segment Annual %Employee StatisticsFacilites By RegionGross ProfitImmunology RevenueImmunology Revenue AnnualInfectious Diseases RevenueInfectious Diseases Revenue AnnualInnovative Medicine Revenue Breakdown AnnualInternational Sales By SegmentInterventional Solutions Revenue AnnualInventoriesLong Lived Assets By RegionMedical Devices RevenueMedical Devices Revenue AnnualMedtech Revenue Breakdown AnnualNeurosciences RevenueNeurosciences Revenue AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology RevenueOncology Revenue AnnualOPEX SegregationOrthopaedics Revenue AnnualPharmaceutical Revenue BreakdownProperty And Equipment SegregationPulmonary Hypertension RevenuePulmonary Hypertension Revenue AnnualRevenue By RegionRevenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Square Footage By RegionSurgery Revenue AnnualUs Sales By SegmentVision Revenue Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Gross Profit (2016 - 2025)

Historic Gross Profit for Johnson & Johnson (JNJ) over the last 17 years, with Q4 2025 value amounting to $16.6 billion.

  • Johnson & Johnson's Gross Profit rose 782.22% to $16.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $63.9 billion, marking a year-over-year increase of 421.68%. This contributed to the annual value of $63.9 billion for FY2025, which is 421.68% up from last year.
  • According to the latest figures from Q4 2025, Johnson & Johnson's Gross Profit is $16.6 billion, which was up 782.22% from $16.7 billion recorded in Q3 2025.
  • Johnson & Johnson's 5-year Gross Profit high stood at $16.7 billion for Q3 2025, and its period low was $13.8 billion during Q2 2022.
  • Over the past 5 years, Johnson & Johnson's median Gross Profit value was $15.0 billion (recorded in 2023), while the average stood at $15.1 billion.
  • Per our database at Business Quant, Johnson & Johnson's Gross Profit soared by 3375.01% in 2021 and then crashed by 1407.26% in 2022.
  • Over the past 5 years, Johnson & Johnson's Gross Profit (Quarter) stood at $16.1 billion in 2021, then fell by 14.07% to $13.8 billion in 2022, then increased by 5.59% to $14.6 billion in 2023, then increased by 5.45% to $15.4 billion in 2024, then rose by 7.82% to $16.6 billion in 2025.
  • Its Gross Profit was $16.6 billion in Q4 2025, compared to $16.7 billion in Q3 2025 and $16.1 billion in Q2 2025.